Nuvation Bio (NUVB) Non-Current Deffered Revenue (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Non-Current Deffered Revenue of $151.9 million for Q1 2026, up 1015.66% year-over-year from $13.6 million in Q1 2025, and up 4.16% quarter-over-quarter from $145.8 million in Q4 2025.
Nuvation Bio (NUVB) Non-Current Deffered Revenue (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Non-Current Deffered Revenue for 5 consecutive years, with $151.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue rose 1015.66% year-over-year to $151.9 million; the TTM figure through Mar 2026 stood at $151.9 million (up 1015.66% YoY), while the FY2025 annual figure was $145.8 million, changed N/A from the prior year.
- Non-Current Deffered Revenue rose to $151.9 million in Q1 2026 per NUVB's latest filing, from $145.8 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $151.9 million in Q1 2026 and bottomed at $7.9 million in Q3 2024.
- Historically, Non-Current Deffered Revenue has averaged $88.0 million across 3 years, with a median of $142.8 million in 2025.
- Annual changes were most pronounced in 2025 — Non-Current Deffered Revenue soared 1722.11% — and 2026, when it jumped 1015.66%.
- Nuvation Bio's Non-Current Deffered Revenue stood at $7.9 million in 2024, then soared by 1737.21% to $145.8 million in 2025, then grew by 4.16% to $151.9 million in 2026.
- Business Quant data shows NUVB's Non-Current Deffered Revenue at $151.9 million in Q1 2026, $145.8 million in Q4 2025, and $144.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | 151.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 151.12 Mn |
| Mar 31, 2026 | 151.89 Mn |
| Dec 31, 2025 | 145.82 Mn |
| Sep 30, 2025 | 144.62 Mn |
| Jun 30, 2025 | 142.78 Mn |
| Mar 31, 2025 | 13.61 Mn |
| Sep 30, 2024 | 7.94 Mn |
| Jun 30, 2024 | 9.16 Mn |
| Sep 30, 2021 | 181,000.00 |
| Jun 30, 2021 | 177,000.00 |
| Mar 31, 2021 | 167,000.00 |
| Dec 31, 2020 | 157,000.00 |